Baby Bathing and Hygiene Products Patents: Leaders & Filing Trends 2026
- 50.6% of records sit with five companies. The top 5 assignees account for 158 of the 312 records in scope, while a long tail of 69 ranked companies fills the rest.
- Filing has cooled from its 2017 peak. Annual filings ran from 17 in 2017 down through 7 in 2021 to 3 in 2024, a 57% drop over that three-year span.
- Formulation chemistry dominates the IPC mix. A61K medicinal preparations (72.4%) and A61Q cosmetics use (61.9%) cover most records, well ahead of C11D detergent compositions at 41.0%.
Filing growth compares 2021 (7 records) with 2024 (3) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 312 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape covers 312 published records at the intersection of baby bath products, baby shampoo and tear-free formulation claims, cross-referenced against surfactant mildness, eye-sting reduction, foam stability, fragrance allergen control, rinse feel and packaging safety. The scope runs from 2015 through the 2026-07-31 data cut-off, capturing both the formulation chemistry (surfactant systems, mild cleansing bases) and the downstream safety and sensory claims that distinguish an infant-grade product from a general personal-care one.
Filing activity peaked in 2017 at 17 records and has since declined, with the most recent complete year, 2024, sitting well below that peak. Because publication typically lags filing by around 18 months, the last one to two years in any trend chart will always look thinner than they eventually turn out to be — a reader should treat 2025 and 2026 as still filling in rather than as evidence of a further slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Three views of the same 312-record dataset: how filing volume has moved over time, how concentrated ownership is among the ranked assignees, and which IPC subclasses carry the claim density.
A 2017 peak followed by a multi-year decline
Annual filings fell from 7 in 2021 to 3 in 2024, a 57% drop over that three-year span. That is the most recent period that can be read as a complete trend; 2025 and 2026 figures are still incomplete due to normal publication lag.
Formulation and cosmetic-use classes dominate
A61K (medicinal preparations) appears on 72.4% of the 312 records and A61Q (cosmetics use) on 61.9%, meaning most filings combine the two. C11D (detergents and cleaning compositions) reaches 41.0%, while polymer-related classes C08F and C08L each sit at 10.6% — smaller but still active pockets of claim activity.
Shares are the percentage of the 312 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Baby Bathing and Hygiene Products with Eureka
This page is one run against one query. Ask Eureka your own question about baby bathing and hygiene products and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
Microbiome-compatible cosmetics
The systems and methods of the disclosure provide, inter alia, cosmetic products, e.g., finished cosmetic products that may be considered to be "biome-friendly" or "biome-compatible." The systems and methods of the disclosure may provide for use of cosmetic products, e.g., finished cosmetic products, that may be used in combination with bacteria, e.g., non-pathogenic bacteria, e.g., ammonia oxidizing bacteria, which may be used in the form of a preparation or composition to be applied to a subject.Filed as US20180369129A1, assigned to MBX LLC, published 2018-12-27.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5641480A | Hair care compositions comprising heteroatom containing alkyl aldonamide compounds | 321 |
| 2 | US4717498A | Dimethicone copolyol sulfosuccinates | 95 |
| 3 | US7803403B2 | Low-irritation compositions and methods of making the same | 63 |
| 4 | US6642198B2 | Clear cleansing detergent systems | 63 |
| 5 | US4849127A | Dimethicone copolyol sulfosuccinates | 59 |
| 6 | US20020123438A1 | Clear cleansing detergent systems | 57 |
| 7 | EP1045021A1 | Composition comprising a mixture of alkoxylated mono-, di- and triglycerides and glycerine | 57 |
| 8 | EP0250181A2 | Mild detergent compositions | 53 |
| 9 | US4426310A | Low-irritation shampoo | 52 |
| 10 | US20060134045A1 | Personal care compositions comprising plant fiber | 48 |
Citation counts reflect the searched corpus and skew toward older filings; treat them as a signal of influence on later work, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for R&D and IP strategy
Reading the concentration, the class mix and the citation pattern together points to where claim space is occupied and where it is thinner.
Ownership is concentrated but not closed
Five companies hold 158 of the 312 records in scope, yet the ranked list runs to 69 companies, most with only a handful of filings. That combination — a concentrated top and a long tail — usually means the core surfactant-mildness and tear-free claims are well covered, while adjacent formulation angles remain open to new entrants.
Activity has cooled from its 2017 peak
Filings dropped from 7 in 2021 to 3 in 2024. Combined with zero recent-year activity across the leading assignees in this dataset, it suggests the category has moved from active build-out toward maintenance of existing positions — though 2025-2026 figures are not yet complete enough to confirm a continued decline.
Formulation claims outweigh packaging and delivery
A61K and A61Q together cover most of the dataset, confirming that mildness and cosmetic-use formulation chemistry is the primary battleground. C08F and C08L polymer classes, each at 10.6%, mark a smaller but distinct cluster around polymeric conditioning or thickening agents worth separate tracking.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to baby bathing and hygiene products, with the prior art for and against each one.
Who holds the ground, and who is moving
The leader board is topped by a single assignee with 38 records, well ahead of the fifth-place company at 26 and the tenth at 10 — a steep drop-off that flattens quickly into the long tail.
A clear top position
The leading assignee holds 38 records, noticeably ahead of the fifth-ranked company at 26. That gap suggests one company built an early, broad position rather than the field arriving at its current shape through many similarly sized filers.
A steep drop into the tail
By tenth place, record counts have fallen to 10, and the ranking continues out to 69 companies. Most of that tail files only occasionally, which is typical of a category where core chemistry is established but sensory and safety refinements keep attracting smaller players.
Momentum has stalled across the top
Every one of the leading assignees shows zero filings in the latest year, including a -100% year-on-year change for one active filer. Given publication lag, this likely overstates the slowdown, but it is consistent with a category past its filing peak rather than one still accelerating.
| Assignee | Recent year | YoY |
|---|---|---|
| Johnson & Johnson Consumer Inc. | 0 | — |
| Symrise GmbH & Co. KG | 0 | — |
| Lubrizol Advanced Materials, Inc. | 0 | — |
| Innospec Ltd. | 0 | — |
| AOBiome LLC | 0 | -100% |
| Procter & Gamble Co. | 0 | — |
| DuPont Tate & Lyle Bio Products Company, LLC | 0 | — |
| Colgate-Palmolive Company | 0 | — |
Where to take this analysis
The dataset points to specific follow-up work depending on whether the goal is freedom-to-operate, portfolio strategy or identifying acquisition targets.
Screen the under-claimed branches
Fragrance-allergen masking and sulfate-free foam stability show thinner coverage than the core tear-free and mildness claims. A focused prior-art pull on these branches before drafting can confirm how much room actually exists.
Explore white space in EurekaTrack the leading assignees' maintenance activity
Zero recent-year filings from the top companies could mean consolidation onto existing claims rather than retreat. Watching continuations and family expansions on their existing grants is more informative than watching for new filings alone.
Monitor assignee activity in EurekaRe-run citation analysis against newer families
The most-cited records here are older; a fresh look at which recent families cite them shows which companies are building on that foundation now.
Run citation analysis in EurekaCommon questions about this landscape
The ranking covers 69 companies, with the leader holding 38 of the 312 records in scope and the fifth-place company holding 26. The top 5 combined account for 158 records, or 50.6% of the field, while the top 10 reach 72.8%. Beyond that, coverage thins into a long tail of companies with only a handful of filings each, so freedom-to-operate work should focus first on the concentrated top group.
Filings peaked in 2017 at 17 records and have declined since, falling from 7 in 2021 to 3 in 2024, a 57% drop over that span. That 2021-2024 window is the most reliable read because publication typically lags filing by about 18 months, so 2025 and 2026 figures are still incomplete. On the evidence available, the category looks past its most active filing period rather than accelerating.
Most records sit in A61K (medicinal preparations, 72.4% of the 312 records) and A61Q (cosmetics use, 61.9%), reflecting the formulation-chemistry core of tear-free and mild-surfactant claims. C11D detergent and cleaning compositions cover 41.0% of records, and smaller polymer-related clusters (C08F, C08L, each 10.6%) point to conditioning or thickening agent work. Because records often carry more than one class, these shares add up to more than 100%.
The gaps sit in the sub-areas with thinner relative coverage than the dominant surfactant-mildness and tear-free claims: fragrance-allergen masking, sulfate-free foam stability, rinse-feel sensory additives, packaging-integrated dosing safety and microbiome-compatible preservation. These are not zero-filing areas, but they carry noticeably less claim density than the core chemistry, which is where a first-filed, narrowly drafted claim has the best chance of standing on its own prior art.
It is concentrated at the top but not closed off entirely. Five companies hold just over half of all 312 records (50.6%), and ten companies hold nearly three-quarters (72.8%), yet the ranking still runs to 69 distinct assignees. That shape — a dominant leader, a clear second tier, then a long tail of occasional filers — is typical of a mature but not fully consolidated category, and it means smaller players can still stake out claims outside the crowded core.
Research Baby Bathing and Hygiene Products in depth with Eureka
Go past this page: query the whole baby bathing and hygiene products corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.